Parexel said today that it would go private after Pamplona Capital agreed to buy the pharmaceutical research services company in a deal valued at $5 billion.
Pamplona is slated to pay $88.10 per share for Parexel, which is a 5% premium to the stock’s close on Monday.
Get the full story at our sister site, Medical Design & Outsourcing.
The post Pamplona Capital to acquire Parexel in $5B deal appeared first on MassDevice.